Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

NCT02388048 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphoblastic, Chronic

Interventions

DRUG: Ibrutinib + ofatumumab

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto